Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW171, a novel 2+1 T-cell Targeting Bispecific Antibody for Mesothelin-expressing Cancers
June 17, 2024 06:00 ET
|
Zymeworks Inc.
VANCOUVER, British Columbia, June 17, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional...
Correction: Amarna Therapeutics announces formation of Scientific Advisory Board to support advancement of groundbreaking Nimvec™ AM510 gene therapy against Type 1 Diabetes
June 17, 2024 05:39 ET
|
Amarna Therapeutics
Amarna Therapeutics announces formation of Scientific Advisory Board to support advancement of groundbreaking Nimvec™ AM510 gene therapy against Type 1...
Amarna Therapeutics announces formation of Scientific Advisory Board to support advancement of groundbreaking Nimvec™ AM510 gene therapy against Type 1 Diabetes
June 17, 2024 05:23 ET
|
Amarna Therapeutics
Amarna Therapeutics announces formation of Scientific Advisory Board to support advancement of groundbreaking Nimvec™ AM510 gene therapy against Type 1...
Grifols’ Biotest receives FDA approval for innovative Yimmugo® immunoglobulin to treat primary immunodeficiencies
June 17, 2024 04:20 ET
|
Grifols, S.A.
With Biotest-developed Yimmugo, Grifols adds to its remarkable franchise of intravenous and subcutaneous immunoglobulins to meet strong demand Yimmugo, already approved for production and marketing...
Adalvo obtiene la primera aprobación de la UE para la pluma precargada de liraglutida como medicamento genérico
June 17, 2024 00:36 ET
|
ADALVO LIMITED
SAN ĠWANN, Malta, June 16, 2024 (GLOBE NEWSWIRE) -- Adalvo anuncia la exitosa aprobación DCP para la pluma precargada de liraglutide, lo que constituye la primera aprobación de medicamento genérico...
Adalvo obtém primeira aprovação genérica da UE para caneta pré-cheia com liraglutida
June 17, 2024 00:36 ET
|
ADALVO LIMITED
SAN ĠWANN, Malta, June 17, 2024 (GLOBE NEWSWIRE) -- Adalvo anuncia a aprovação bem-sucedida do DCP para a caneta pré-cheia com liraglutida, marcando-a como a primeira aprovação genérica na UE. Como...
アダルボ (Adalvo)、リラグルチド・プレフィルド・ペン (Liraglutide Pre-Filled Pen) のEU初のジェネリック承認を取得
June 17, 2024 00:36 ET
|
ADALVO LIMITED
マルタ、サン・グワン発, June 17, 2024 (GLOBE NEWSWIRE) -- アダルボは、リラグルチド・プレフィルド・ペンのDCP承認に成功したことを発表した。これはEU初のジェネリック承認となる。 IQVIAの報告によると、2型糖尿病の治療に適応するビクトーザ (Victoza®)...
Adalvo Mendapatkan Persetujuan Generik UE Pertama untuk Pena Pra-Isi Liraglutide
June 17, 2024 00:36 ET
|
ADALVO LIMITED
SAN ĠWANN, Malta, June 17, 2024 (GLOBE NEWSWIRE) -- Adalvo mengumumkan keberhasilan mendapatkan persetujuan DCP untuk pena pra-isi Liraglutide, dengan menandainya sebagai persetujuan generik pertama...
Adalvo 獲得利拉魯肽預裝填注射筆首個歐盟仿製藥批准
June 17, 2024 00:36 ET
|
ADALVO LIMITED
馬耳他聖瓜安, June 17, 2024 (GLOBE NEWSWIRE) -- Adalvo 宣布其利拉魯肽預裝筆成功獲得分散式程序 (DCP) 批准，成為歐盟首個獲得仿製藥批准的產品。 根據 IQVIA 的報告，這種多肽藥物作為 Victoza® 預裝填注射筆的生物等效性版本用於治療 2 型糖尿病，在 2023 年全球銷售額超過 48 億美元。 利拉魯肽的成功開發，突顯了...
Adalvo 的 Liraglutide 預充式注射筆成為歐盟首款獲得批准的仿製藥
June 17, 2024 00:36 ET
|
ADALVO LIMITED
馬爾他聖瓜安, June 17, 2024 (GLOBE NEWSWIRE) -- Adalvo 宣布 Liraglutide 預充式注射筆成功取得 DCP 批准，成為歐盟首款獲得批准的仿製藥。 根據 IQVIA 的報告數據統計，用於治療第二型糖尿病的 Victoza® 預充式注射筆的生物等效版本，這類多肽藥品於 2023 年的全球銷售額超過 48 億美元。 Liraglutide...